These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38812074)

  • 41. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension.
    Humbert M; McLaughlin V; Gibbs JSR; Gomberg-Maitland M; Hoeper MM; Preston IR; Souza R; Waxman AB; Ghofrani HA; Escribano Subias P; Feldman J; Meyer G; Montani D; Olsson KM; Manimaran S; de Oliveira Pena J; Badesch DB
    Eur Respir J; 2023 Jan; 61(1):. PubMed ID: 36041750
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sotatercept: First Approval.
    Kang C
    Drugs; 2024 Jul; 84(7):857-862. PubMed ID: 38904927
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma.
    Zhu R; Zheng Y; Dirks NL; Vadhavkar S; Jin JY; Peng K; Holweg CTJ; Olsson J; Matthews JG; Putnam WS
    Pulm Pharmacol Ther; 2017 Oct; 46():88-98. PubMed ID: 28843617
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients.
    Zheng B; Yu XQ; Greth W; Robbie GJ
    Br J Clin Pharmacol; 2016 May; 81(5):918-28. PubMed ID: 26659791
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Population pharmacokinetics of subcutaneous C1-inhibitor for prevention of attacks in patients with hereditary angioedema.
    Pawaskar D; Tortorici MA; Zuraw B; Craig T; Cicardi M; Longhurst H; Li HH; Lumry WR; Martinez-Saguer I; Jacobs J; Bernstein JA; Riedl MA; Katelaris CH; Keith PK; Feussner A; Sidhu J
    Clin Exp Allergy; 2018 Oct; 48(10):1325-1332. PubMed ID: 29998524
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Population Pharmacokinetic Analysis of Dorzagliatin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus.
    Wang K; Feng L; Zhang J; Zou Q; Xu F; Sun Z; Tang F; Chen L
    Clin Pharmacokinet; 2023 Oct; 62(10):1413-1425. PubMed ID: 37537410
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis.
    Adedokun OJ; Xu Z; Liao S; Strauss R; Reinisch W; Feagan BG; Sandborn WJ
    Clin Ther; 2020 Jan; 42(1):157-174.e4. PubMed ID: 31982148
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women.
    Sherman ML; Borgstein NG; Mook L; Wilson D; Yang Y; Chen N; Kumar R; Kim K; Laadem A
    J Clin Pharmacol; 2013 Nov; 53(11):1121-30. PubMed ID: 23939631
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treating Pulmonary Arterial Hypertension With Sotatercept: A Meta-Analysis.
    Uddin N; Ashraf MT; Sam SJ; Sohail A; Ismail SM; Paladini A; Syed AA; Mohamad T; Varrassi G; Kumar S; Khatri M
    Cureus; 2024 Jan; 16(1):e51867. PubMed ID: 38327917
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials.
    Patel P; Howgate E; Martin P; Carlile DJ; Aarons L; Zhou D
    Br J Clin Pharmacol; 2018 Jan; 84(1):52-63. PubMed ID: 28833380
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B.
    Diao L; Li S; Ludden T; Gobburu J; Nestorov I; Jiang H
    Clin Pharmacokinet; 2014 May; 53(5):467-77. PubMed ID: 24452809
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Population pharmacokinetic analysis of dupilumab in adult and adolescent patients with asthma.
    Zhang L; Gao Y; Li M; Xu C; Davis JD; Kanamaluru V; Lu Q
    CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):941-952. PubMed ID: 34313019
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Population Pharmacokinetic Model of Macitentan and Its Active Metabolite Aprocitentan in Healthy Volunteers and Patients with Pulmonary Arterial Hypertension.
    Bartolucci R; Dosne AG; Csonka D; Pérez-Ruixo JJ; Magni P; Poggesi I
    Clin Pharmacokinet; 2021 Dec; 60(12):1605-1619. PubMed ID: 34159557
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials.
    Suleiman AA; Khatri A; Minocha M; Othman AA
    Clin Pharmacokinet; 2019 Mar; 58(3):375-387. PubMed ID: 30123942
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
    Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
    Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
    Guo F; Letrent SP; Sharma A
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous "manual syringe" injection or intravenously in women with HER2-positive early breast cancer.
    Quartino AL; Hillenbach C; Li J; Li H; Wada RD; Visich J; Li C; Heinzmann D; Jin JY; Lum BL
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):77-88. PubMed ID: 26645407
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Factors Affecting Time-Varying Clearance of Cyclosporine in Adult Renal Transplant Recipients: A Population Pharmacokinetic Perspective.
    Mao J; Qiu X; Qin W; Xu L; Zhang M; Zhong M
    Pharm Res; 2021 Nov; 38(11):1873-1887. PubMed ID: 34750720
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease.
    Vande Casteele N; Mould DR; Coarse J; Hasan I; Gils A; Feagan B; Sandborn WJ
    Clin Pharmacokinet; 2017 Dec; 56(12):1513-1523. PubMed ID: 28353055
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Population pharmacokinetics of losmapimod in healthy subjects and patients with rheumatoid arthritis and chronic obstructive pulmonary diseases.
    Yang S; Lukey P; Beerahee M; Hoke F
    Clin Pharmacokinet; 2013 Mar; 52(3):187-98. PubMed ID: 23254770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.